Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
PGF-H52G3 | Human | Human PlGF-1 Protein, GST Tag | ![]() |
||
PGF-H5255 | Human | Human PLGF-3 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
PGF-H5256 | Human | Human PlGF-1 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
PGF-H52H5 | Human | Human PlGF-1 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
PGF-M52H0 | Mouse | Mouse PLGF / PGF Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
PGF-R52H0 | Rhesus macaque | Rhesus macaque PLGF / PGF Protein, His Tag | ![]() |
![]() ![]() |
|
PGF-H5229 | Human | Human PlGF-2 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) at 2 μg/mL (100 μL/well) can bind Human PlGF-1 Protein, Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.1-3 ng/mL (QC tested).
The purity of Human PLGF-3 Protein, Fc Tag (Cat. No. PGF-H5255) is more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Approved | Momenta, Mylan Nv | YESAFILI | EU | Myopia, Degenerative; Diabetic Retinopathy; Retinal Vein Occlusion; Diabetes Complications; Macular Edema | Viatris Ltd | 2023-09-15 | Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Approved | Qilu Pharmaceutical Co Ltd | Mainland China | Macular Degeneration; Diabetic macular oedema | Qilu Pharmaceutical Co Ltd | 2023-12-13 | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details | |
Aflibercept biosimilar (Amgen) | ABP-938 | Approved | Amgen Inc | PAVBLU | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema | Amgen Inc | 2024-08-23 | Macular Edema; Wet Macular Degeneration; Vascular Diseases; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
Aflibercept | BAY-865321; BAT-86-5321 | Approved | Regeneron Pharmaceuticals Inc, Bayer AG | Eylea, 艾力雅 | United States | Macular Degeneration; Macular Edema | Regeneron Pharmaceuticals Inc | 2011-11-18 | Wet Macular Degeneration; Corneal Neovascularization; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Retinopathy of Prematurity; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic Retinopathy; Macular Degeneration; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Vitreous Hemorrhage; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Drug-Related Side Effects and Adverse Reactions; Diabetic macular oedema; Retinitis Pigmentosa; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Central Serous Chorioretinopathy; Colonic Neoplasms; Neoplasms; Choroid Diseases; Rectal Neoplasms; Diabetes Mellitus, Type 2; Glaucoma, Neovascular; Macular Edema; Cataract; Diabetes Mellitus, Type 1 | Details |
Aflibercept biosimilar (HEXAL/Sandoz) | SOK-583A1; SOK583A1; SOK-583 | Approved | Sandoz, Hexal | ENZEEVU, Afqlir | United States | Wet Macular Degeneration | Sandoz Inc | 2024-08-09 | Retinal Diseases; Wet Macular Degeneration; Macular Degeneration | Details |
Aflibercept biosimilar (Celltrion) | CT-P42 | Approved | Celltrion Inc | Eydenzelt | South Korea | Wet Macular Degeneration; Diabetic macular oedema | Celltrion Inc | 2024-05-30 | Wet Macular Degeneration; Diabetic macular oedema | Details |
Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Endometrial Neoplasms; Urethral Neoplasms; Breast Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Ureteral Neoplasms; Genital Neoplasms, Female; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Astrocytoma; Gliosarcoma; Lung Neoplasms; Lymphoma; Metastatic breast cancer; Prostatic Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Glioma; Carcinoma, Neuroendocrine; Uterine Neoplasms; Fallopian Tube Neoplasms; Retinal Vein Occlusion; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Small Cell Lung Carcinoma; Skin Melanoma; Leukemia; Solid tumours; Multiple Endocrine Neoplasia Type 1; Leiomyosarcoma; Rectal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Papillary; Ovarian Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Carcinoma, Ovarian Epithelial; L | Details |
Aflibercept biosimilar (Bioeq) | FYB-203 | Approved | Formycon AG | AHZANTIVE, Baiama | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Retinal Vein Occlusion; Macular Degeneration | Formycon AG | 2024-06-28 | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
Aflibercept biosimilar (Samsung Bioepis) | SB-15; AM003; SB15 | Approved | Samsung Bioepis Co Ltd | OPUVIZ, Opuviz, AFILIVU | United States | Diabetic macular oedema; Macular Edema; Wet Macular Degeneration; Diabetic Retinopathy | Samsung Bioepis Co Ltd | 2024-05-20 | Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Macular Degeneration; Diabetic Retinopathy | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
Aflibercept biosimilar (Shilpa Biologicals) | SBDM-03 | Phase 3 Clinical | Shilpa Biologicals Pvt Ltd | Wet Macular Degeneration | Details |
Aflibercept Biosimilar(Rophibio) | RBS-001 | Phase 3 Clinical | Rophibio Inc | Wet Macular Degeneration; Macular Degeneration | Details |
Aflibercept Biosimilar (Alvotech Swiss) | AVT-06; AVT-29 | Phase 3 Clinical | Alvotech Swiss Ag | Vascular Diseases; Macular Degeneration | Details |
Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
Anti-placental growth factor monoclonal antibody | αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 | Phase 2 Clinical | Thrombogenics, Bioinvent International Ab | Solid tumours; Retinal Telangiectasis; Ovarian Neoplasms; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Carcinoma, Hepatocellular; Diabetes Mellitus; Macular Degeneration | Details |
4D-150 | 4D-150 | Phase 2 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Colorectal Neoplasms | Details |
PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
EB-105 | EB-105 | Phase 1 Clinical | Eluminex Biosciences (Suzhou) Ltd | Diabetic macular oedema; Diabetic Retinopathy | Details |
Aflibercept biosimilar(Generium) | GNR-098 | Phase 1 Clinical | Generium Pharmaceuticals | Macular Degeneration | Details |
Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details |
This web search service is supported by Google Inc.